Enicepatide and Petrelintide: Why the Next Weight-Loss Peptide Conversation Is Moving Beyond GLP-1 Alone
Roche’s ADA 2026 obesity update puts enicepatide, petrelintide, and amylin-incretin combinations at the center of today’s weight-loss peptide conversation. Here is the cautious science behind the momentum.
June 1, 20268 min read
Read Article ›